Erythropoietin treatment for patients with sepsis and severe lung injury

A randomized placebo-controlled trial in patients with sepsis-associated acute respiratory distress syndrome evaluating whether recombinant human erythropoietin added to standard therapy, compared with placebo plus standard therapy, improves oxygenation and lung function, reduces inflammatory marker levels, shortens the duration of mechanical ventilation, and reduces mortality

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14700344

Enrollment

100

Registered

2026-04-15

Start date

2021-03-01

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-associated acute respiratory distress syndrome in adult intensive care unit patients requiring ventilatory support and blood purification treatment. Respiratory

Interventions

Eligible adult patients with sepsis-associated acute respiratory distress syndrome will be randomly assigned in a 1:1 ratio, using a random number table based on the order of admission, to a placebo g

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Adult patients aged 18 years or older 2.Admitted to the Intensive Care Unit of Shaw Hospital affiliated with Nanjing Medical University between March 2021 and March 2023 3.Clinical diagnosis of sepsis and acute respiratory distress syndrome according to the study diagnostic criteria 4.Required ventilator support and blood purification treatment 5.Able to comply with study procedures and had complete follow-up clinical data 6.Informed about the study and provided voluntary written informed consent

Exclusion criteria

Exclusion criteria: 1.Cardiogenic shock 2.Concurrent fungal or viral infections 3.Severe gastrointestinal, liver, or kidney failure 4.Coagulopathy 5.Malignant tumors 6.Hemodynamic instability or inability to maintain blood pressure with vasoactive drugs 7.Immune system deficiency

Countries

China

Contacts

Public ContactJinghui;Wei Yang;Zhao

;

yangjinghui911@163.com;zhaowei8051@163.com+86 18905184048;+86 13605158009

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 1, 2026